ResearchMoz

Computational Biology (Pharmacodynamics, Cellular Modeling, Computational Genomics, Proteomics, Pharmacogenomics, Pharmacokinetics, Human Simulation Software, Drug Discovery & Development) Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018

Transparency Market Research
Published Date » 2013-05-07
No. Of Pages » 112
   
 The computational biology market is predicted to have a notable growth owing to its wide use by biotechnology and pharmaceutical companies to reduce the incidences of late stage failures of their drugs and to thereby curb R&D expenditure. Computational biology is also assisting in reducing the extensive use of humans in trials and is therefore useful for pediatric trials, trials on pregnant women and orphan disease research. 
   
 This report analyses the global market for computational biology by two main types of studies-cellular modeling and disease modeling. Each of these segments has been further analyzed by various studies with use of simulation, right from drug discovery to drug development. The market has also been bifurcated on the basis of tools which include...
Table of Content

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Scope Of The Report
1.4 Research Methodology
1.4.1 Sources
1.4.1.1 Secondary Research
1.4.1.2 Primary Research
1.4.1.3 Models
1.5 Assumptions

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Computational Biology Market (2011 & 2018)
2.2 Global Computational Biology Market, by Types, 2011 (USD Million)

Chapter 3 Global Computational Biology Market Dynamics
3.1 Market Overview
3.2 Drivers
3.2.1 Failure Of Drug Candidates in Late Stage of Clinical Trials
3.2.1.1 Average Cost to Develop One New Drug (1975 -2011) (USD Million)
3.2.1.2 Trend of Rise in Failure of Phase II Clinical Trials (2006- 2012)
3.2.1.3 Reasons For Failure (%) in Phase II & Phase III
3.2.2 Enhanced Computational Tools
3.2.3 Improved Government Funding &Industrial Support
3.3 Restraints
3.3.1 Lack of Standardization
3.3.2 Non-Verified Predictive Models
3.4 Challenges
3.4.1 Shortage of Skilled Resources
3.4.2 Data Storage
3.5 Opportunities
3.5.1 Cloud Computing
3.5.2 Modelling And Simulations in Paediatrics Drug Development
3.6 Porters Five Forces Analysis
3.6.1 Bargaining Power of Suppliers
3.6.2 Bargaining Power of Buyers
3.6.3 Threat of New Entrants
3.6.4 Threat Of Substitutes
3.6.5 Competitive Rivalry
3.7 Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis: Global Computational Biology Market, by Geography
3.8 End User Analysis
3.8.1 End User Analysis: Global Computational Biology Market, 2011 & 2018 (%)

Chapter 4 Global Computational Biology Market, by Applications
4.1 Introduction
4.1.1 Cellular Modelling and Simulation
4.1.1.1 Computational Genomics
4.1.1.1.1 Global Computational Genomics Market Revenues, 2010 – 2018 (USD Million)
4.1.1.2 Computational Proteomics
4.1.1.2.1 Global Computational Proteomics Market Revenues, 2010 – 2018 (USD Million)
4.1.1.3 Pharmacogenomics
4.1.1.3.1 Global Computational Pharmacogenomics Market Revenues, 2010 – 2018 (USD Million)
4.1.1.4 Others (Metabolomics/ Transcriptomics)
4.1.1.4.1 Global Computational Others (Metabolomics/Transcriptomics) Market Revenue, 2010 – 2018 (USD Million)
4.1.2 Disease Modelling And Simulation Applications / CADD (Computer Aided Drug Design)
4.1.2.1 Drug Discovery
4.1.2.1.1 Global Computational Drug Discovery Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2 Target Identification
4.1.2.1.2.1 Global Computational Target Identification Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.3 Target Validation
4.1.2.1.3.1 Global Computational Target Validation Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.4 Lead Identification/Discovery
4.1.2.1.4.1 Global Computational Lead Identification Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.5 Lead Optimization
4.1.2.1.5.1 Global Computational Lead Optimization Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1 Drug Development
4.1.2.1.1 Preclinical
4.1.2.1.1.1 Global Computational Preclinical Trials Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2 Clinical Trials
4.1.2.1.2.1 Global Computational Clinical Trials Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2.2 Phase I
4.1.2.1.2.3 Global Computational Clinical Trials Phase I Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2.4 Phase II
4.1.2.1.2.5 Global Computational Clinical Trials Phase II Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2.6 Phase III
4.1.2.1.2.7 Global Computational Clinical Trials Phase III Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.3 Human Body Simulation Software
4.1.2.1.3.1 Global Computational Human Simulation Software Market Revenues, 2010 – 2018 (USD Million)

Chapter 5 Global Computational Biology Market, by Tools
5.1 Overview
5.2 Database
5.2.1 Global Computational Biology Database Market Revenues, 2010 – 2018 (USD Million)
5.3 IT Infrastructure (Hardware)
5.3.1 Global Computational Biology Hardware Market Revenues, 2010 – 2018 (USD Million)
5.4 Analysis Software & Services
5.4.1 Global Computational Biology Software Market Revenues, 2010 – 2018 (USD Million)

Chapter 6 Global Computational Biology Market, by Services
6.1 Overview
6.2 In-House Computational Biology
6.2.1 Global In-House Computational Biology Market Revenues, 2010 – 2018 (USD Million)
6.3 External/Contract Computational Biology
6.3.1 Global Contract Computational Biology Market Revenues, 2010 – 2018 (USD Million)

Chapter 7 Global Computational Biology Market, by Geography
7.1 Overview
7.2 North America
7.2.1 North America Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.3 Europe
7.3.1 Europe Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.4 Asia
7.4.1 Asia Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.5 ROW
7.5.1 Row Computational Biology Market Revenues, 2010 – 2018 (USD Million)

Chapter 8 Market Share Analysis
8.1 Market Share by Key Players
8.1.1 Global Computational Biology Market Share Analysis of Key Players, 2011 (%)

Chapter 9 Recommendations
9.1 Success Strategies
9.1.1 Rigorous Research and Development (R&D) Initiatives
9.1.2 Investing in Emerging Economies
9.1.3 Investing in High-End Technologies
9.1.4 Collaborations, Mergers and Acquisitions
9.2 Barriers to be Considered
9.2.1 High Cost of Investment

Chapter 10 Company Profiles
10.1 Accelrys
10.1.1 Company Overview
10.1.2 Financial Overview
10.1.3 Product Portfolio And Services
10.1.4 Business Strategy
10.1.5 Recent Developments
10.2 Certara
10.2.1 Company Profile
10.2.2 Financial Overview
10.2.3 Product Portfolio And Services
10.2.4 Business Strategy
10.2.5 Recent Developments
10.3 Chemical Computing Group Inc.
10.3.1 Company Profile
10.3.2 Financial Overview
10.3.3 Product Portfolio
10.3.4 Business Strategy
10.3.5 Recent Developments
10.4 Compugen, Ltd
10.4.1 Company Profile
10.4.2 Financial Overview
10.4.3 Business Strategy
10.4.4 Recent Developments
10.5 Entelos
10.5.1 Company Profile
10.5.2 Financial Overview
10.5.3 Product Portfolio And Services
10.5.4 Business Strategy
10.5.5 Recent Developments
10.6 Genedata AG
10.6.1 Company Profile
10.6.2 Financial Overview
10.6.3 Product Portfolio And Services
10.6.4 Business Strategy
10.6.5 Recent Developments
10.7 Insilico Biotechnology AG
10.7.1 Company Profile
10.7.2 Financial Overview
10.7.3 Product Portfolio
10.7.4 Business Strategy
10.7.5 Recent Developments
10.8 Leadscope, Inc
10.8.1 Company Profile
10.8.2 FinancialOverview
10.8.3 Product Portfolio
10.8.4 Business Strategy
10.8.5 Recent Developments
10.9 Nimbus Discovery LLC
10.9.1 Company Profile
10.9.2 Financial Overview
10.9.3 Product Portfolio
10.9.4 Business Strategy
10.9.5 Recent Developments
10.10 RhenoviaPharma SAS
10.10.1 Company Profile
10.10.2 Financial Overview
10.10.3 Product Portfolio And Services
10.10.4 Business Startegy
10.10.5 Recent Developments
10.11 Schrodinger
10.11.1 Company Overview
10.11.2 Financial Overview
10.11.3 Product Portfolio And Services
10.11.4 Business Strategy
10.11.5 Recent Developments
10.12 Simulation Plus, Inc.
10.12.1 Company Profile
10.12.2 Financial Overview
10.12.3 Product Portfolio And Services
10.12.4 Business Strategy
10.12.5 Recent Developments

List of Tables

List of Tables

TABLE 1 Global Computational Biology Market: Snapshot (2011 & 2018)
TABLE 2 R&D Function by Expenditure (%)
TABLE 3 Global Computational Biology Market Revenues, by Segments, 2010 – 2018 (USD Million)
TABLE 4 Global Cellular Modeling and Biology Simulation Market Revenues, by Types, 2010 – 2018 (USD Million)
TABLE 5 Global Cellular Modeling and Biology Simulation Market Revenues, by Geography, 2010 – 2018 (USD Million)
TABLE 6 Global Disease Modeling and Simulation Market Revenues, by Types, 2010 - 2018 (USD Million)
TABLE 7 Global Disease Modeling and Simulation Market Revenues, by Geography, 2010 - 2018 (USD Million)
TABLE 8 Global Computational Drug Development Market Revenues, by Types, 2010 - 2018 (USD Million)
TABLE 9 Software Packages for PBPK Modeling
TABLE 10 Global Computational Biology Market Revenues, by Tools, 2010- 2018 (USD Million)
TABLE 11 Global Computational Services Market Revenues, by Services, 2010- 2018 (USD Million)
TABLE 12 Global Computational Biology Market, by Geography, 2010- 2018 (USD Million)

List of Figures

List of Figures

FIG. 1 Global Computational Biology: Market Segmentation
FIG. 2 Global Computational Biology Market, By Types, 2011 (USD Million)
FIG. 3 Average Cost to Develop one New Drug (1975 -2011) (USD Million)
FIG. 4 Trend of Rise in Failure of Phase II Clinical Trials (2006- 2012)
FIG. 5 Reasons for Failure (%) in Phase II & Phase III
FIG. 6 Porter’s Five Forces Analysis for Computational Biology Market
FIG. 7 Market Attractiveness Analysis: Global Computational Biology Market, By Geography
FIG. 8 End User Analysis: Global Computational Biology Market, 2011 & 2018 (%)
FIG. 9 Global Computational Genomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 10 Global Computational Proteomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 11 Global Computational Pharmacogenomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 12 Global Computational Others (Metabolomics/ Transcriptomics) Market Revenue, 2010 – 2018 (USD Million)
FIG. 13 Global Computational Drug Discovery Market Revenues, 2010 – 2018 (USD Million)
FIG. 14 Global Computational Target Identification Market Revenues, 2010 – 2018 (USD Million)
FIG. 15 Global Computational Target Validation Market Revenues, 2010 – 2018 (USD Million)
FIG. 16 Global Computational Lead Identification Market Revenues, 2010 – 2018 (USD Million)
FIG. 17 Global Computational Lead Optimization Market Revenues, 2010 – 2018 (USD Million)
FIG. 18 Global Computational Preclinical Trials Market Revenues, 2010 – 2018 (USD Million)
FIG. 19 Global Computational Clinical Trials Market Revenues, 2010 – 2018 (USD Million)
FIG. 20 Global Computational Clinical Trials Phase I Market Revenues, 2010 – 2018 (USD Million)
FIG. 21 Global Computational Clinical Trials Phase II Market Revenues, 2010 – 2018 (USD Million)
FIG. 22 Global Computational Clinical Trials Phase III Market Revenues, 2010 – 2018 (USD Million)
FIG. 23 Global Computational Human Simulation Software Market Revenues, 2010 – 2012 (USD Million)
FIG. 24 Global Computational Biology Database Market Revenues, 2010 – 2018 (USD Million)
FIG. 25 Global Computational Biology Hardware Market Revenues, 2010 – 2018 (USD Million)
FIG. 26 Global Computational Biology Software Market Revenues, 2010 – 2018 (USD Million)
FIG. 27 Global In-House Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 28 Global Contract Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 29 North America Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 30 Europe Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 31 Asia Computational Biology Market Revenue, 2010 – 2018 (USD Million)
FIG. 32 Row Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 33 Global Computational Biology Market Share Analysis Of Key Players, 2011 (%)
FIG. 34 Annual Revenues: Accelrys, 2009 - 2011 (USD Million)
FIG. 35 Annual Revenue: Compugen, 2010 – 2012 (USD Million)
FIG. 36 Annual Revenues: Simulation Plus, Inc., 2010 – 2012 (USD Million)

Upcoming Reports:

Licensed Sports Merchandise Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020
By - Transparency Market Research
Sports licensing includes licensing of symbols, logos, names of players and names of varied sport organizations. The sports body is known as licensor whereas company leasing rights is known as licensee. In particular, licensor selects licensee that helps to enhance the brand image of sports organization and teams. Expenditure on sports merchandise determines the wide polarization of buying habits, with retail and entertainment at one end and e-commerce at the other. Today, consumers are increasingly spending on sport leisure at high end malls and departmental stores. Hence, sports...
Poland: hosiery market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the hosiery market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the hosiery market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...
Nuclear Power Safety Backups Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth And Forecast 2014 - 2020
By - Transparency Market Research
Rapid rise in the global demand for nuclear power is expected to boost the demand for nuclear power industry and thus nuclear power safety backup market. New programs developed by governments worldwide are estimated to propel the demand for nuclear power industry. Post-Fukushima, several governments have recommended installation of backup generators for nuclear power plants to guard against floods and tsunami. Increasing number of countries worldwide is introducing energy generation from nuclear power plants as a part of their generation mix. This is expected to boost the demand for...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

New Drug Shows Early Promise against Heart Attacks and Strokes
Sep 1, 2014  
Sanofi and Regeneron Pharmaceuticals have been working on a new experimental drug that aims to lower cholesterol. Early tests have shown that the drug cuts down risks of heart attacks and strokes in clinical trials by half. The test report says that the results are not conclusive as the analysis was performed retrospectively. The study does provide the positive result that...
Western Africa economies hit by Ebola travel ban
Aug 28, 2014  
With over 1,400 people dead due to the fatal Ebola outbreak in African countries, travel services have either banned or limited operations to the western region, severely hitting economies of the area. Budgetary resources are being utilized rapidly and economic growth has dropped by 4% as international projects and trips have been cancelled. Transport companies have cut off the region...
Fonterra Ties Up With Beingmate to Tap into China’s Baby Food Market
Aug 28, 2014  
Fonterra Co-Operative Group Ltd. will partner with Beingmate Group Co, China’s biggest infant formula manufacturer to increase its reach in the Chinese market. The New Zealand-based company makes this move with the intent to grab a bigger market share in China after it suffered many setbacks in the food-safety scandal last year.   This partnership will also help Beingmate...
Chinas Leading Asset-Management Company Aims for IPO
Aug 28, 2014  
China’s biggest asset-management company plans to go public by the end of 2015. Chinese authorities are constantly ramping up their interests towards introducing mixed ownership to state-owned huge companies and call for more private capital investments into the economy. According to the news report, China Huarong Asset Management Co., Ltd. will collaborate with eight investors...
Warren Buffet Helps Burger King with Tim Horton Deal
Aug 27, 2014  
Renowned investor Warren Buffet plans to finance Burger King Worldwide Inc.’s acquisition of Tim Hortons Inc., the Canadian coffee chain. Berkshire Hathaway Inc., Warren Buffet’s firm will invest through preferred shares, it is speculated. Nearly 25% of the deal’s financing would be handled by Berkshire. The precise aim for Warren Buffet’s participation is yet...